A PROSPECTIVE RANDOMIZED, OPEN-LABEL PHASE 2 STUDY OF IMMUNE CHECKPOINT INHIBITION, NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN COMBINATION WITH RADIATION THERAPY IN PRETREATED PATIENTS WITH METASTATIC PANCREATIC CANCER OR BILIARY TRACT CANCER - CheckPAC

Herlev & Gentofte Hospital, Oncology Dept.0 个研究点目标入组 140 人开始时间: 2016年6月21日最近更新: 2021年4月26日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 140

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•8.3SUBJECT INCLUSION CRITERIA
•Patients with:
•Signed informed consent
•oSubjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care
•oSubjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study
•Histopathological confirmation of pancreatic adenocarcinoma or biliary tract cancer prior to entering this study OR histopathological confirmation of carcinoma in the setting of clinical and radiological characteristics which, together with the pathology, are consistent with a diagnosis of PC or biliary tract cancer
•At least one measurable primary in-situ (or locally-recurrent) or metastatic tumor must be present and, in the opinion of radiation oncologist, be amenable to RT as planned in the protocol and at least one additional metastatic tumor that will not undergo RT and which is measurable according to RECIST 1.1 criteria. Both lesions must be accessible for image-guided percutaneous biopsy
•There is no upper limit on the number of prior chemotherapy regimens received. Patients must have received and failed or intolerance to at least one line of prior systemic chemotherapy with gemcitabine or platinum-containing regimens for unresectable and/or metastatic PC or BTC
•Age > 18 years and older
•Life expectancy greater than 3 months
•ECOG/WHO Performance Status (PS) 0-1
•Patients must have normal organ and marrow function as defined below:
•oWhite blood cell count (WBC) = 2 x 10?/L
•oAbsolute neutrophil count (ANC) = 1.5 x 10?/L
•oHemoglobin = 5,6 mmol/l
•oPlatelet count = 100 x 10?/L
•oSerum bilirubin = 1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin < 3.0 mg/dL)
•oASAT/ALAT = 3 x ULN ( < 5 x ULN if known liver metastasis)
•oPP = 40 or INR = 1.5
•oSerum creatinine = 1.5 x ULN or CrCl = 40 mL/min (using the Cockcroft-Gault formula)
•Women of childbearing potential (WOCBP) must use method(s) of contraception as indicated in Appendix 27.10. For a teratogenic study drug and/or when there is insufficient information to assess teratogenicity (preclinical studies have not been done), a highly effective method(s) of contraception (failure rate of less than 1% per year) is required. The individual methods of contraception and duration should be determined in consultation with the investigator. WOCBP must follow instructions for birth control when the half-life of the investigational drug is greater than 24 hours, contraception should be continued for a period of 30 days plus the time required for the investigational drug to undergo five half-lives. The half-life of nivolumab and ipilimumab is up to 25 days and 18 days, respectively. WOCBP should therefore use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug
•WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of nivolumab
•Women must not be breastfeeding
•Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year (Appendix 27.10). The investigator shall review contraception methods

排除标准

•8.4SUBJECT EXCLUSION CRITERIA
•Patients with:
•Malignant ascites that is clinically detectable by physical examination or is symptomatic. Evidence of radiographic ascites that is not clinically significant will not be exclusion criteria
•Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
•No chemotherapy, radiotherapy, or major surgery within the last 2 weeks prior to entering the study
•Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results
•Patients should be excluded if they have an active, known or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
•Patients should be excluded if they are positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
•Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
•As there is potential for hepatic toxicity with nivolumab or nivolumab/ipilimumab combinations, drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab and ipilimumab-containing regimen
•Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
•Allergies and Adverse Drug Reaction
•oHistory of allergy to study drug components
•oHistory of severe hypersensitivity reaction to any monoclonal antibody
•WOCBP who are pregnant or breastfeeding
•Women with a positive pregnancy test at enrollment or prior to administration of study medication
•Patients are excluded if they have active brain metastases or leptomeningeal metastases. Subjects with brain metastases are eligible if metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for [lowest minimum is 4 weeks or more] after treatment is complete and within 28 days prior to the first dose of nivolumab administration. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration

研究者

发起方

Herlev & Gentofte Hospital, Oncology Dept.

相似试验

尚未招募

2 期

A PROSPECTIVE, RANDOMIZED, OPEN-LABEL PHASE 2 STUDY TO EVALUATE THE SUPERIORITY OF INOTUZUMAB OZOGAMICIN MONOTHERAPY VERSUS ALLR3 FOR INDUCTION TREATMENT OF CHILDHOOD HIGH RISK FIRST RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIARelapsed Acute Lymphoblastic Leukemia and Relapsed Childhood leukemia10024324

NL-OMON53624Pfizer4

招募中

1 期

A study with InO vs. ALLR3 in treating childhood leukemiaAcute Lymphoblastic Leukemia (ALL)MedDRA version: 21.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2022-000186-40-NLPfizer Inc.100

进行中（未招募）

1 期

EUCTR2022-000186-40-DKPfizer Inc.100

进行中（未招募）

1 期

EUCTR2022-000186-40-NOPfizer Inc.100

进行中（未招募）

1 期

EUCTR2022-000186-40-SKPfizer Inc.100